Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
04 avr. 2024 08h45 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA...
BioCorRx Reports Business Update for 2023
02 avr. 2024 08h30 HE
|
BioCorRx Inc
ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
Transgene prévoit des avancées significatives sur son portefeuille d’immunothérapies en 2024 et étend sa visibilité financière jusqu’au 4ème trimestre 2025
27 mars 2024 12h45 HE
|
Transgene S.A.
Résultats annuels 2023 et point sur l’activité TG4050 : de nouveaux résultats attendus en 2024 sur l’actif phare de TransgeneLes autres programmes cliniques et de recherche et innovation...
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
27 mars 2024 12h45 HE
|
Transgene S.A.
2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation (R&I) activity...
Evaxion Announces Business Update and Full Year 2023 Financial Results
27 mars 2024 07h30 HE
|
Evaxion Biotech
Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named...
DHT Holdings, Inc. Business Update
17 janv. 2024 16h15 HE
|
DHT Holdings, Inc.
HAMILTON, BERMUDA, January 17, 2024 – DHT Holdings, Inc. (NYSE:DHT) (“DHT” or the “Company”) today provides the following business update: The Company estimates its P&L break-even level for the...
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
16 janv. 2024 16h01 HE
|
Celyad Oncology SA
Three main pillars to unlock the potential of proprietary technology platforms and intellectual property: A proprietary non-gene editing technology platform based on multiplexing of short hairpin...
DHT Holdings, Inc. Business Update
10 janv. 2024 16h15 HE
|
DHT Holdings, Inc.
HAMILTON, BERMUDA, January 10, 2024 – DHT Holdings, Inc. (NYSE:DHT) (“DHT” or the “Company”) today provides the following business update: For the fourth quarter of 2023, the Company estimates time...
Evaxion Announces Business Update and Third Quarter 2023 Financial Results
19 déc. 2023 16h15 HE
|
Evaxion Biotech
Christian Kanstrup joined Evaxion as Chief Executive Officer in SeptemberEvaxion has launched its refined strategy with an increased focus on value realization via partnerships based upon the...
Eguana Announces Closing of First Tranche of Private Placement of Units and Provides Corporate Update
08 déc. 2023 17h49 HE
|
Eguana Technologies Inc.
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta,...